Literature DB >> 2556643

Sequence-specific RNA binding by the HIV-1 Rev protein.

M L Zapp1, M R Green.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) Rev protein acts post-transcriptionally to increase the amounts of the viral gag-pol and env messenger RNAs in the cytoplasm of infected cells. The mechanism of Rev action is uncertain. Possibilities include an accelerating effect on the rate of export of its mRNA targets from the nucleus and/or modulation of the splicing of pre-mRNAs. Both the gag-pol and env mRNAs contain a sequence that is required for responsiveness to Rev--the Rev responsive element, RRE. Here we show that Rev is a sequence-specific binding protein, whose binding site is the RRE. This information should help to clarify the mechanism by which Rev acts.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556643     DOI: 10.1038/342714a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  170 in total

1.  Polyvalent Rev decoys act as artificial Rev-responsive elements.

Authors:  T L Symensma; S Baskerville; A Yan; A D Ellington
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  R region sequences in the long terminal repeat of a murine retrovirus specifically increase expression of unspliced RNAs.

Authors:  A M Trubetskoy; S A Okenquist; J Lenz
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

3.  A nucleocapsid functionality contained within the amino terminus of the Ty1 protease that is distinct and separable from proteolytic activity.

Authors:  Joseph F Lawler; Gennady V Merkulov; Jef D Boeke
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 4.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

5.  Human immunodeficiency virus type 1 Rev activation can be achieved without Rev-responsive element RNA if Rev is directed to the target as a Rev/MS2 fusion protein which tethers the MS2 operator RNA.

Authors:  S Venkatesan; S M Gerstberger; H Park; S M Holland; Y Nam
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

6.  Posttranscriptional regulation by the human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex proteins through a heterologous RNA binding site.

Authors:  D McDonald; T J Hope; T G Parslow
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

7.  Specific binding of the human T-cell leukemia virus type I Rex protein to a short RNA sequence located within the Rex-response element.

Authors:  H P Bogerd; L S Tiley; B R Cullen
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

8.  Inhibition of human immunodeficiency virus type 1 Rev function by a Rev mutant which interferes with nuclear/nucleolar localization of Rev.

Authors:  S Kubota; R Furuta; M Maki; M Hatanaka
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  RU5 of Mason-Pfizer monkey virus 5' long terminal repeat enhances cytoplasmic expression of human immunodeficiency virus type 1 gag-pol and nonviral reporter RNA.

Authors:  Stacey Hull; Kathleen Boris-Lawrie
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Polypyrimidine tract-binding protein and heterogeneous nuclear ribonucleoprotein A1 bind to human T-cell leukemia virus type 2 RNA regulatory elements.

Authors:  A C Black; J Luo; C Watanabe; S Chun; A Bakker; J K Fraser; J P Morgan; J D Rosenblatt
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.